Zanidatamab
- Generic Name
- Zanidatamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2169946-15-8
- Unique Ingredient Identifier
- Z20OC92TDI
- Background
According to Zymeworks, "ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function. These combined mechanisms of action have led to significant anti-tumor activity in preclinical models of breast and gastric cancers."
- Associated Conditions
- -
- Associated Therapies
- -
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Conditions
- Metastatic HER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06435429
- Locations
- ๐บ๐ธ
Arizona Oncology Tucson - Wilmot, Tucson, Arizona, United States
๐บ๐ธUSC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS, Los Angeles, California, United States
๐บ๐ธRocky Mountain Cancer Centers, Denver, Colorado, United States
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- Conditions
- Breast CancerHER2-positive
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05035836
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- Conditions
- Advanced Malignancies
- Interventions
- Drug: TislelizumabDrug: PamiparibDrug: SitravatinibDrug: BGB-15025Drug: ZanidatamabDrug: TemozolomideDrug: OciperlimabDrug: BAT1706Drug: FruquintinibDrug: BGB-A445Drug: SurzebiclimabDrug: LenvatinibDrug: LBL-007
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 300
- Registration Number
- NCT04164199
- Locations
- ๐จ๐ณ
Henan Cancer Hospital, Zhengzhou, Henan, China
๐จ๐ณThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
๐จ๐ณThe First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.